AstraZeneca has established a global partnership with Axa Pharmaceuticals to explore the clinical application of combination therapies in the field of blood tumors.

Guide: Development of Bcl-2 inhibitors and second-generation BTK inhibitorsToday, Axa Pharma and AstraZeno jointly announced a global partnership to explore the clinical application of combination therapies in the field of blood tumorsthe two sides will conduct clinical studies on the combination of the original innovative target Bcl-2 selective inhibitors and BTK (Bruton tyrosinine kinase) inhibitors to evaluate the clinical effectiveness of the combination drug in patients with relapsed chronic lymphocytic leukemia/small lymphocyte lymphoma (Chronic Lymphocytic Leukemia/Small LympyLymoma, CLL/SLL)The study is a global multi-center, open Ib/II dose efficacy exploration study, planned in the United States, Europe, Australia and moreCLL/SLL is a mature B lymphocyte clone proliferation tumor, is the highest incidence of adult leukemia in developed countries in Europe and the United States, accounting for about 30% of all leukemia, the annual incidence rate of 2-6/10million people, 65 years of age up to 12.8/100,000 peopleAlthough the first-line solution significantly improves the initial treatment and remission rate of CLL/SLL patients, but the need for long-term medication to control the disease, once relapsed often the prognosis is very poorRecent studies have found that BTK inhibitors in combination with Bcl-2 inhibitors have the advantages of high depth response rate, and may even become long-term treatment for limited cycle therapy, providing the possibility of "clinical cure" and discontinuation of CLL/SLL patients, which provides a basis for the exploration of combination drug use.